Reformulation of Marketed Drugs Expected to Boost the Epilepsy Market in the US by 2019: TechNavio

LONDON--(BUSINESS WIRE)--

The Epilepsy Market in US is expected to post a CAGR of 4.85 percent from 2014-2019, growing in response to serious unmet medical need in the sector.

About the Report

According to a new report from tech focused research firm TechNavio, reformulation of marketed drugs will be a major trend to watch in this market over the projected period. Drug delivery systems like transdermal patches, ER formulations and orally disintegrating tablets help increase the efficacy of drugs either by increasing patient compliance or by increasing the bioavailability of the drug.

“New-generation anti-epileptic drugs offer efficacy along with enhanced tolerability, pharmacokinetic properties and reduced side effects as compared to traditional drugs,” says Ghaus.

Key Information Covered in the Report:

• Market segmentation, size and forecast through 2019
• Market Growth Drivers:
  • Unmet Medical Needs
  • For a full detailed list, view our report.
• Market Challenges:
  • Generic Erosion
  • For a full detailed list, view our report.
• Market Trends:
  • Reformulation of Marketed Drugs
  • For a full detailed list, view our report.
• Key Vendors:
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • UCB SA
• Other Prominent Vendors:
• Abbvie
• Eisai
• F. Hoffmann-La Roche
• H. Lundbeck
• http://finance.yahoo.com/news/reformulation-marketed-drugs-expected-boost-163000802.html